The appointment of Dr. Brem is seen as a strategic move to enhance the board's expertise in clinical development and regulatory approval processes, particularly as Galectin Therapeutics advances its lead drug, belapectin, for the treatment of MASH cirrhosis. Richard E. Uihlein, Chairman of the Board, emphasized Dr. Brem's pioneering contributions to neurosurgical oncology and his ability to translate innovative science into meaningful therapies for patients. Dr. Brem's appointment is expected to bolster the company's strategic priorities and support upcoming milestones in drug development.
Dr. Brem's qualifications are underscored by his impressive track record, which includes over 416 peer-reviewed publications and numerous patents. He has been continuously funded by the NIH for over four decades and is a member of the National Academy of Medicine. His leadership experience extends to serving as a director for multiple private and public companies, making him a valuable addition to Galectin's board.
The company believes that Dr. Brem's extensive medical and management experience will significantly contribute to its mission of developing novel therapies for chronic liver disease and cancer. The board's decision to appoint Dr. Brem reflects a commitment to strengthening its governance and operational execution as it navigates the complexities of drug development and regulatory landscapes.
